Company Overview
Company Type: Public Company
Website: www.vaxil-bio.com
Number of Employees: 5
Ticker: VXL (TSXV)
Year Founded: 2006


Business Description
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment. The company was founded in 2006 and is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
EBITDA
(0.6)
EBIT
(0.6)
Cash & ST Invst.
1.1
Net Income
(0.6)
Total Debt
0.0
Total Assets
1.1
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023

Key Professionals
Name
Title
Levin, Gadi 
CEO & Chairman
Rootenberg, Alan Mark
Chief Financial Officer
Kovjazin, Riva
Senior Scientist & Member of Scientific Advisory Board

Key Board Members
Name
Title
Levin, Gadi 
CEO & Chairman
Kellen, Ari S.
Independent Director & Member of Scientific Advisory Board
Berelowitz, Michael 
Special Advisor to the Board
Bloch, Daniel N.
Director
Kovjazin, Riva
Senior Scientist & Member of Scientific Advisory Board
Langer, Shawn 
Independent Director & Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
3400 One First Canadian Place | Toronto, ON | M5X 1A4 | Canada

Current and Pending Investors
Silver Cloud Ventures Limited, Yorkville Advisors Global LP

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.02
Market Cap (mm)
2.1
Open
 0.02
Shares Out. (mm)
137.0
Previous Close
 0.02
Float %
91.8%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.02/ 0.01
Diluted EPS Excl. Extra Items
0.00
52 wk High/Low
 0.03/ 0.01
P/Diluted EPS Before Extra
NM
Volume (mm)
0.16
Avg 3M Dly Vlm (mm)
0.10
Beta 5Y
-


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSXV:VXL - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Short Wave Pharma Inc. (Pending)
Short Wave Pharma Inc. a pre-clinical stage biotech company, focuses on the development of IP-protected formulations and delivery methods of psychedelics-based medicine for the treatment of mental illness, chronic pain and neuro degenerative diseases. The company is based in Israel.

United States and Canada
Biotechnology
-
-
-
Emerge Resources Corp.
The Company is an exploration stage company located at Suite 1128 - 789 West Pender Street, Vancouver, BC, V6C 1H2, engaged in the acquisition, exploration and development of mineral resource properties located in Canada.

United States and Canada
Gold
-
0.00
0.00
Sheldonco Ltd.
Sheldonco Ltd. develops and maintains real estate properties. The company is based in Tel Aviv, Israel. Sheldonco Ltd. was acquired by Vaxil Bio Ltd.

Africa / Middle East
Real Estate Development
0.00
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Oct-14-2021
Cancelled
Merger/Acquisition
Buyer
Short Wave Pharma Inc.
Vaxil Bio Ltd. (TSXV:VXL)

2.02
Nov-09-2020
Dec-10-2020
Private Placement
Target
Vaxil Bio Ltd. (TSXV:VXL)


0.63
May-26-2020
Cancelled
Private Placement
Target
Vaxil Bio Ltd. (TSXV:VXL)


2.24
Sep-10-2019
Mar-04-2020
Private Placement
Target
Vaxil Bio Ltd. (TSXV:VXL)


0.10
Dec-05-2017
Jan-30-2018
Private Placement
Target
Vaxil Bio Ltd. (TSXV:VXL)


1.47
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-02-2023
Executive Changes - CEO
Vaxil Bio Ltd. Announces CEO Changes
Aug-02-2023
Executive Changes - CFO
Vaxil Bio Ltd. Announces CFO Changes
Apr-27-2023
Auditor Going Concern Doubts
Vaxil Bio Ltd. Auditor Raises 'Going Concern' Doubt
Apr-20-2023
Shareholder/Analyst Calls
Vaxil Bio Ltd. - Shareholder/Analyst Call
Apr-20-2023
Annual General Meeting
Vaxil Bio Ltd., Annual General Meeting, Apr 20, 2023


Advisors
Most Recent Auditor
Zeifmans LLP
Private Placement Advisors
M Partners Inc., Sunel Securities Inc.
Public Offering Advisors
Crowe Horwath (Israel), Crowe LLP, Shnitzer, Gotlieb, Sharon & Co.


Most Recent Auditor
Zeifmans LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 04:00 AM
VXL
Vaxil Bio Ltd 2023_10_05
Reports
14
GlobalData

Sep 15, 2023 04:15 AM
VXL
Vaxil Bio Ltd (VXL.CVE) - Medical Devices Product Pipeline Summary
Reports
20
GlobalData

Sep 12, 2023 03:58 AM
VXL
Vaxil Bio Ltd (VXL.CVE) - Financial Analysis Review
Reports
76
S&P Global Compustat

Sep 07, 2023 03:58 AM
VXL
Vaxil Bio Ltd 2023_09_07
Reports
14
GlobalData

Aug 23, 2023 06:45 AM
VXL
Vaxil Bio Ltd (VXL.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
35
S&P Global Compustat

Jul 06, 2023 03:27 AM
VXL
Vaxil Bio Ltd 2023_07_06
Reports
14
GlobalData

Jun 09, 2023 08:52 AM
VXL
Vaxil Bio Ltd (VXL.CVE) - Medical Devices Product Pipeline Summary
Reports
20
GlobalData

Jun 08, 2023 05:08 AM
VXL
Vaxil Bio Ltd (VXL.CVE) - Financial Analysis Review
Reports
76
S&P Global Compustat

Jun 01, 2023 04:21 AM
VXL
Vaxil Bio Ltd 2023_06_01
Reports
14
GlobalData

May 09, 2023 04:06 AM
VXL
Vaxil Bio Ltd (VXL.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
35


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Kellen M.D., Ari S.

5,542,183

4.05

0.1

Mar-20-2023


Langer M.D., Shawn 

4,985,000

3.64

0.1

Mar-20-2023


Levin B.Com., C.A., CPA, M.B.A., MBA, Gadi 

758,381

0.55

0.0

Aug-02-2023


CARRET Asset Management, LLC

20,000

0.01

0.0

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Levin B.Com., C.A., CPA, M.B.A., MBA, Gadi 
758,381
101,181

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
CorVax (Future), Drug Discovery and Development Platform (Future), ImMucin (Future), MTbuVax (Future), MUC1-SP (Future), VaxHit (Future)


Upcoming Events
Date/Time
Type
Nov-24-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-28-2023
Jun-30-2023
Vaxil Bio Ltd. (TSXV:VXL)
SEDAR
Interim Financial Statements
256 KB
May-29-2023
Mar-31-2023
Vaxil Bio Ltd. (TSXV:VXL)
SEDAR
Interim Financial Statements
252 KB
Apr-27-2023
Dec-31-2022
Vaxil Bio Ltd. (TSXV:VXL)
SEDAR
Annual Financial Statements
403 KB
Apr-27-2023
Dec-31-2022
Vaxil Bio Ltd. (TSXV:VXL)
SEDAR
Annual Financial Statements
134 KB
Apr-27-2023
Dec-31-2022
Vaxil Bio Ltd. (TSXV:VXL)
SEDAR
Annual Financial Statements
57 KB
Apr-24-2023
-
Vaxil Bio Ltd. (TSXV:VXL)
SEDAR
News Releases
24 KB
Mar-30-2023
-
Vaxil Bio Ltd. (TSXV:VXL)
SEDAR
Management Proxy Materials
539 KB
Mar-30-2023
-
Vaxil Bio Ltd. (TSXV:VXL)
SEDAR
Management Proxy Materials
115 KB
Mar-30-2023
-
Vaxil Bio Ltd. (TSXV:VXL)
SEDAR
Management Proxy Materials
508 KB
Mar-30-2023
-
Vaxil Bio Ltd. (TSXV:VXL)
SEDAR
Management Proxy Materials
98 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Kellen M.D., Ari S. (Independent Director & Member of Scientific Advisory Board)
Jan-22-2021
Common Shares
635,000
67,828
Derivative Exercise and Retained Stock
11.46
Exchange Announcement
Langer M.D., Shawn  (Independent Director & Member of Scientific Advisory Board)
Jan-22-2021
Common Shares
635,000
67,828
Derivative Exercise and Retained Stock
12.74
Exchange Announcement
Levin B.Com., C.A., CPA, M.B.A., MBA, Gadi  (CEO & Chairman)
Nov-23-2020
Common Shares
338,381
26,350
Open Market Acquisition
80.57
Exchange Announcement
Kellen M.D., Ari S. (Independent Director & Member of Scientific Advisory Board)
Nov-23-2020
Common Shares
557,183
43,388
Private Acquisition
11.18
Exchange Announcement
Goren, David  (Former Director)
Nov-23-2020
Common Shares
466,543
36,330
Private Acquisition
New
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Levin, Gadi 
CEO & Chairman
-
-
gadi@a2zas.com
Kellen, Ari S.
Independent Director & Member of Scientific Advisory Board
-
-

Berelowitz, Michael 
Special Advisor to the Board
-
-

Bloch, Daniel N.
Director
-
-

Kovjazin, Riva
Senior Scientist & Member of Scientific Advisory Board
-
-
-
Langer, Shawn 
Independent Director & Member of Scientific Advisory Board
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Levin, Gadi 
CEO & Chairman
-
-
gadi@a2zas.com
Rootenberg, Alan Mark
Chief Financial Officer
905-731-5315 Ext. 29
-
arootenberg@auryxgold.com
Kovjazin, Riva
Senior Scientist & Member of Scientific Advisory Board
-
-
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
